Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Dec 17, 2022
Product Development
Neoantigens Part III: Picking up the pace
The field ends a busy 4Q22 with Moderna’s highly anticipated, heavily scrutinized data
BioCentury | Jul 1, 2022
Discovery & Translation
T cell aneuploidy after CRISPR TRAC editing; plus Poseida, Cellectis and more
BioCentury’s roundup of translational news
BioCentury | Jun 17, 2022
Emerging Company Profile
BlueSphere: TCR discovery at scale
Sole investor and integrated health system UPMC brings a client’s perspective on the Pitt spinout’s TCR cell therapies
BioCentury | Dec 18, 2021
Discovery & Translation
Regeneron’s humanized mice for therapeutic TCR discovery; plus Pattern, Century and more
BioCentury’s roundup of translational news
BioCentury | Nov 10, 2021
Emerging Company Profile
Marengo taps T cell stimulation white space with $80M from ATP
The company’s antibodies against germline-encoded regions of the TCR show promise as single agents for cancer
BioCentury | Jun 29, 2018
Product R&D
Highly personal
Why GV and Canaan backed Pact Pharma’s hyperpersonalized cancer approach
BioCentury | Nov 13, 2017
Preclinical News
UCL, Autolus develop CARs against T cell malignancies that partially preserve normal T cells
Items per page:
1 - 10 of 13